TITLE:
A Study of Persons With Gout Who Do Not Respond to or Are Allergic to Conventional Therapy

CONDITION:
Gout

INTERVENTION:
Puricase

SUMMARY:

      This is a randomized, open-label, multicenter, parallel-groups study of multiple intravenous
      doses of Puricase, administered intravenously, in 40 patients with symptomatic gout.
      Subjects must wash out of any uric acid-lowering agents for one week before being dosed, and
      must refrain from using such agents throughout the study.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to 90 Years
Criteria:

        Inclusion Criteria:

        Subjects to be included in the study are:

          -  Outpatients of either gender, age 18 or older

          -  Diagnosed with symptomatic gout refractory to conventional therapy or unable to
             tolerate conventional therapy (for example: having one or more tophi and/or having
             experienced a gout flare within the previous 6 months and/or having chronic, gouty
             arthritis)

          -  Hyperuricemic: screening serum uric acid must be >=8 mg/dL.

          -  The patient must be willing and able to give informed consent and adhere to
             visit/protocol schedules (Consent must be given before any study procedures are
             performed)

          -  Women of childbearing potential must have a negative serum pregnancy test and must
             use an approved birth control method during their participation in the protocol. Such
             methods include oral, injectable, or implantable contraceptives; IUDs and barrier
             contraceptives in combination with spermicide

        Exclusion Criteria:

        Subjects to be excluded are those for whom any of the following apply:

          -  Unstable coronary artery disease or uncontrolled hypertension

          -  History of end stage renal disease requiring dialysis

          -  History of liver disease, as defined by baseline serum transaminase elevation >3X the
             upper limit of normal in the absence of any other known cause

          -  Organ transplant recipient requiring immunosuppressive therapy

          -  Concurrent use of prednisone at a dose >10 mg qd (or equivalent) at or within one
             week before dosing

          -  Concurrent use of uric acid-lowering agents

          -  Prior treatment with Puricase or other recombinant uricase

          -  An acute gout flare within one week prior to first treatment with Puricase
             (exclusive of chronic synovitis/arthritis) requiring use of medication which violates
             the protocol

          -  glucose-6-phosphate dehydrogenase deficiency

          -  A history of anaphylactic reaction to a recombinant protein or porcine derivatives

          -  Lactation

          -  Has taken an investigational drug within 4 weeks prior to study drug administration
             or plans to take an investigational agent during the study

          -  Known allergy to urate oxidase or PEGylated products

          -  Has any other medical or psychological condition which, in the opinion of the
             investigator, might create undue risk to the patient or interfere with the patient's
             ability to comply with the protocol requirements
      
